Our staff
Our Staff
ICRA has a dedicated staff from different background and countries with strong experience in managing clinical trials. The chance we had to work in several research institutions as investigators and CRO as Clinical Research Associate is a great asset that allows us to expand our skills and helps us easily and pleasingly customize solutions to the many and varied challenges of sponsors.
In addition to their qualification and their experience, ICRA’ staffs are continuously trained in ICH-GCP, ethic, appropriate SOPs, protocols and related documents of any new study contracted.
ICRA’s staffs are really committed to the development of your products and takes total seriousness, accountability and responsibility to work as an extension of sponsor’s team. Such commitment leads irrevocably to brilliant success of projects.
Experience of staff
2019
Mars
The DRC compassionate Ring vaccination with VSV-ZEBOV vaccine .
2018
September - CHAIN study
« Building the evidence base for care of acutely ill, undernourished children in limited resource setting” in Banfora, Burkina Faso.
2016
From May to September
«Vaccination cohort study in people at possible risk of late transmission of Ebola virus disease from survivors, to determine the effect of natural seropositivity on the immunogenicity and safety of the VSV-ZEBOV vaccine (ERC.0002732)» in Guinea Conakry.
2015 to 2016
From February 2015 to April 2016:
The Guinean EBOLA Vaccine Trial including a ring vaccination trial (Phase III) and a Frontline Workers trial performed by 20 monitors (14 for the first and 6 for the second).
2013 to 2014
From November 2013 to June 2014:
GSK epidemiological study named EPI MALARIA 06 run in Burkina Fasso (Sapone and Nouna).
2012 to 2013
From May 2012 to September 2013: Unblended Monitoring at CVD Mali (PsA-007)
Accountability of the study vaccines (PsA and Mencevax) at the Centre for Vaccine Development (CVD) in Mali. 1200 subjects have been randomized into three vaccine groups. The Meningitis Vaccine Programme (MVP) was the sponsor of the study.
2011 to 2012
From June 2011 to April 2012
Epidemiology of meningococcal carriage in five countries of the African Meningitis Belt. Including Senegal (Niakhar). Study sponsored by the LSHTM.
2011 to 2014
From Mars 2011 to June 2014
GSK epidemiological study named EPI MALARIA 01 run in Lambaréné-Gabon.
2010
From July to November : Unblended Monitoring at CVD Mali (PsA-006)
To ensure that unblended procedures were respected and the accountability of the study vaccines (PsA and Mencevax) was reconciled at the Centre for Vaccine Development (CVD) in Mali. 6000 subjects have been randomized into three age groups and two vaccine groups. The study was sponsored by the Meningitis Vaccine Programme (MVP).
2010 to 2014
From Mars 2010 to April 2014
GSK anti-pneumocoque vaccine trial (Pneumo 64) run in Ouagadougou-Burkina Faso (CNRFP) among children with Sickle Cell Diseases.
2010
From January to October : Unblended Monitoring at NHRC Ghana (PsA-004)
To ensure that unblended procedures were respected and the accountability of the study vaccines (PsA and EPI) was reconciled at Navrongo Health Research Centre (NHRC) in Ghana. In this study, a total of 1200 eligible subjects have been randomized into six groups. The study was sponsored by the Meningitis Vaccine Programme. The mission has been successfully done with the congratulations of the sponsor.
2009 to 2011
From July 2009 to April 2011
A phase IV randomised vaccine trial comparing the effectiveness of a Flu vaccine to a control. 10000 subjects aged from 6 months-10 years have been vaccinated in Niakhar (Senegal). This trial was sponsored by the Program for Appropriate Technology in Health (PATH) and run in collaboration between the Institut de Recherche pour le Développement (IRD) and Institut Pasteur de Dakar (IPD).
2007 to 2009
From October 2007 to June 2009
A phase II/III, observer-blind, active controlled vaccine trial against Meningitis in a rural area, Niakhar (PsA-003). The trial was collaboration between Meningitis Vaccine Project (MVP), Institut de Recherche pour le Développement (IRD), the Serum Institute of India Limited (SIIL) and the Program for Appropriate Technology in Health (PATH). 300 subjects aged to 2 – 29 years have been vaccinated with the candidate vaccine or the control.